RxDoctor Payments DataLook up a doctor →

Gini Fleming

Hematology & Oncology · Chicago, ILNPI 1407918964

Payments from drug & device makers

$2,338,847in general payments, 2019–2025

Across 220 payments — averaging $10,631 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$653K
  • Iovance Biotherapeutics, Inc.$475K
  • AstraZeneca$434K
  • Genentech, Inc.$166K
  • Incyte Corporation$146K
  • AbbVie$96K
  • plus $370K from 10 others
$195in research payments, 2019–2025

Across 4 payments — averaging $48.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$195

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,338,847 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$41,401
Medicare patients
127
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →